Beranda › Edema Makula › Texas
Uji klinis Edema Makula di Texas
5 studi untuk Edema Makula mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
- Austin Research Center for Retina, PLLC, Austin
- Austin Retina Associates, Austin
- Austin Retina Associates, Austin
- dan 7 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06962839A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
- Austin Retina Associates ( Site 0008), Austin
- Retina Consultants of Texas ( Site 0001), Bellaire
- Retina Consultants of Texas ( Site 0029), Schertz
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07705555A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
- Texas Retina ( Site 0051), Arlington
- Texas Retina Associates ( Site 0055), Fort Worth
- Retina Consultants of Texas - Katy/Cinco Ranch ( Site 0100), Katy
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07705607A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
- Retina Research Institute of Texas, Abilene
- Austin Retina Associates, PLLC (Austin), Austin
- UT Austin, Austin
- dan 7 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT06990399A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
- Retina Research Institute of Texas, Abilene
- Austin Retina Associates, PLLC (Austin), Austin
- UT Austin, Austin
- dan 7 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT06996080Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.